Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant On Track To File Retigabine For Epilepsy In 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Pending approval, the first-in-class neuronal potassium channel opener would launch in 2009.

You may also be interested in...



Valeant Seeking Return To Growth With New Chief Executive

Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.

Valeant Seeking Return To Growth With New Chief Executive

Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.

Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s Disease

Japanese drug maker says it now plans to file the AMPA receptor antagonist in fiscal fourth quarter 2008, not fiscal 2007.

Topics

UsernamePublicRestriction

Register

PS065417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel